CAPR - Latest News
Capricor Therapeutics, Inc. (CAPR), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $241.0M. Beta to the broader market is 0.53.
The article list below shows the most recent CAPR headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent CAPR Headlines
CAPR INVESTOR ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit before September 28, 2026 Deadline
newsfilecorp.com - Aug 16, 2026
San Diego, California--(Newsfile Corp. - August 16, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Thera
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR
globenewswire.com - Aug 16, 2026
NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Ther
CAPR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026
newsfilecorp.com - Aug 16, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
globenewswire.com - Aug 16, 2026
New class action for Capricor (CAPR) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/28/2026
NASDAQ: CAPR: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Capricor Therapeutics, Inc
globenewswire.com - Aug 15, 2026
Did you buy CAPR securities between December 17, 2025 and July 26, 2026 ? Affected CAPR Investor Summary Who: Capricor Therapeutics, Inc.
How News Affects CAPR Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track CAPR's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked CAPR news questions
- What is the latest CAPR news headline?
- The most recent CAPR headline (Aug 16, 2026) is "CAPR INVESTOR ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit before September 28, 2026 Deadline". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the CAPR news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What CAPR news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual CAPR options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.